Cipher Pharmaceuticals Inc. (CPH.TO)
CAD 14.56
(3.41%)
CAD 14.56
(3.41%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 11.52 Million USD | -16.51% |
| 2022 | 11.08 Million USD | -6.23% |
| 2021 | 11.82 Million USD | -3.07% |
| 2020 | 12.19 Million USD | 4.41% |
| 2019 | 11.68 Million USD | 119.16% |
| 2018 | 5.33 Million USD | -78.88% |
| 2017 | 25.24 Million USD | 179.3% |
| 2016 | -31.82 Million USD | -46707.35% |
| 2015 | -68 Thousand USD | 98.59% |
| 2014 | -4.82 Million USD | -128.3% |
| 2013 | 17.05 Million USD | 610.14% |
| 2012 | 2.4 Million USD | 202.16% |
| 2011 | -2.35 Million USD | -23410.13% |
| 2010 | -9998.40 USD | 99.63% |
| 2009 | -2.71 Million USD | 14.56% |
| 2008 | -3.17 Million USD | 56.7% |
| 2007 | -7.32 Million USD | 29.18% |
| 2006 | -10.34 Million USD | 27.12% |
| 2005 | -14.2 Million USD | -136.24% |
| 2004 | -6.01 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 3.05 Million USD | 89.52% |
| 2024 Q2 | 3.27 Million USD | -5.7% |
| 2023 Q2 | 1.84 Million USD | -21.03% |
| 2023 Q4 | 1.61 Million USD | -53.37% |
| 2023 Q1 | 2.33 Million USD | -5.61% |
| 2023 FY | 9.25 Million USD | -16.51% |
| 2023 Q3 | 3.45 Million USD | 87.17% |
| 2022 Q2 | 3.4 Million USD | 17.07% |
| 2022 Q4 | 2.47 Million USD | 8.59% |
| 2022 FY | 11.08 Million USD | -6.23% |
| 2022 Q1 | 2.9 Million USD | -25.47% |
| 2022 Q3 | 2.28 Million USD | -32.92% |
| 2021 Q4 | 3.89 Million USD | 92.64% |
| 2021 Q1 | 2.07 Million USD | -39.58% |
| 2021 Q2 | 3.82 Million USD | 83.97% |
| 2021 Q3 | 2.02 Million USD | -47.06% |
| 2021 FY | 11.82 Million USD | -3.07% |
| 2020 FY | 12.19 Million USD | 4.41% |
| 2020 Q1 | 3.61 Million USD | -3.21% |
| 2020 Q2 | 2.65 Million USD | -26.43% |
| 2020 Q3 | 2.48 Million USD | -6.43% |
| 2020 Q4 | 3.43 Million USD | 38.22% |
| 2019 Q2 | 2.79 Million USD | 79.99% |
| 2019 Q4 | 3.73 Million USD | 3.84% |
| 2019 Q3 | 3.59 Million USD | 28.57% |
| 2019 FY | 11.68 Million USD | 119.16% |
| 2019 Q1 | 1.55 Million USD | 144.34% |
| 2018 Q2 | 2.91 Million USD | 330.62% |
| 2018 FY | 5.33 Million USD | -78.88% |
| 2018 Q4 | 636 Thousand USD | -42.55% |
| 2018 Q3 | 1.1 Million USD | -61.97% |
| 2018 Q1 | 676 Thousand USD | -91.46% |
| 2017 Q3 | 6.25 Million USD | -2.08% |
| 2017 Q1 | 4.68 Million USD | 145.89% |
| 2017 FY | 25.24 Million USD | 179.3% |
| 2017 Q4 | 7.91 Million USD | 26.65% |
| 2017 Q2 | 6.38 Million USD | 36.26% |
| 2016 Q3 | -20.72 Million USD | -7922.26% |
| 2016 FY | -31.82 Million USD | -46707.35% |
| 2016 Q2 | 265 Thousand USD | 122.96% |
| 2016 Q1 | -1.15 Million USD | 28.41% |
| 2016 Q4 | -10.21 Million USD | 50.74% |
| 2015 Q3 | -2.17 Million USD | -877.14% |
| 2015 FY | -68 Thousand USD | 98.59% |
| 2015 Q4 | -1.61 Million USD | 25.92% |
| 2015 Q2 | 280 Thousand USD | -91.68% |
| 2015 Q1 | 3.36 Million USD | -0.64% |
| 2014 Q4 | 3.38 Million USD | -15.94% |
| 2014 FY | -4.82 Million USD | -128.3% |
| 2014 Q1 | 4.45 Million USD | -53.34% |
| 2014 Q2 | 5.44 Million USD | 22.36% |
| 2014 Q3 | 4.03 Million USD | -26.02% |
| 2013 Q4 | 9.54 Million USD | 198.45% |
| 2013 Q2 | 2.85 Million USD | 100.69% |
| 2013 Q1 | 1.42 Million USD | 9.75% |
| 2013 FY | 17.05 Million USD | 610.14% |
| 2013 Q3 | 3.19 Million USD | 12.12% |
| 2012 Q4 | 1.29 Million USD | 69.04% |
| 2012 FY | 2.4 Million USD | 202.16% |
| 2012 Q1 | 99.22 Thousand USD | 118.61% |
| 2012 Q2 | 172.05 Thousand USD | 73.4% |
| 2012 Q3 | 766.06 Thousand USD | 345.24% |
| 2011 Q2 | -546.19 Thousand USD | 52.09% |
| 2011 FY | -2.35 Million USD | -23410.13% |
| 2011 Q1 | -1.14 Million USD | -2104.44% |
| 2011 Q4 | -533.15 Thousand USD | -122.19% |
| 2011 Q3 | -239.95 Thousand USD | 56.07% |
| 2010 FY | -9998.40 USD | 99.63% |
| 2010 Q3 | -273.3 Thousand USD | -139.07% |
| 2010 Q2 | 699.61 Thousand USD | 237.68% |
| 2010 Q1 | -508.14 Thousand USD | 24.57% |
| 2010 Q4 | 56.87 Thousand USD | 120.81% |
| 2009 Q4 | -673.68 Thousand USD | -32.37% |
| 2009 FY | -2.71 Million USD | 14.56% |
| 2009 Q1 | -651.77 Thousand USD | -567.69% |
| 2009 Q2 | -698.56 Thousand USD | -7.18% |
| 2009 Q3 | -508.93 Thousand USD | 27.15% |
| 2008 Q4 | -97.61 Thousand USD | 15.3% |
| 2008 FY | -3.17 Million USD | 56.7% |
| 2008 Q3 | -115.24 Thousand USD | 93.88% |
| 2008 Q2 | -1.88 Million USD | -59.08% |
| 2008 Q1 | -1.18 Million USD | 35.39% |
| 2007 Q4 | -1.83 Million USD | -38.07% |
| 2007 Q3 | -1.32 Million USD | 37.46% |
| 2007 FY | -7.32 Million USD | 29.18% |
| 2007 Q1 | -1.63 Million USD | -133.58% |
| 2007 Q2 | -2.12 Million USD | -30.02% |
| 2006 Q4 | -698.45 Thousand USD | 65.67% |
| 2006 Q2 | -4.62 Million USD | -61.13% |
| 2006 Q3 | -2.03 Million USD | 56.03% |
| 2006 FY | -10.34 Million USD | 27.12% |
| 2006 Q1 | -2.87 Million USD | 23.78% |
| 2005 Q2 | -4.43 Million USD | -104.77% |
| 2005 Q3 | -3.5 Million USD | 20.95% |
| 2005 Q4 | -3.76 Million USD | -7.48% |
| 2005 FY | -14.2 Million USD | -136.24% |
| 2005 Q1 | -2.16 Million USD | 0.0% |
| 2004 Q2 | -3.94 Million USD | -188.53% |
| 2004 Q1 | -1.36 Million USD | 0.0% |
| 2004 Q3 | 15.59 Million USD | 495.57% |
| 2004 FY | -6.01 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aurora Cannabis Inc. | -46.45 Million CAD | 124.819% |
| Avicanna Inc. | -7.93 Million CAD | 245.329% |
| Avant Brands Inc. | -1.45 Million CAD | 894.555% |
| Cardiol Therapeutics Inc. | -29.78 Million CAD | 138.707% |
| Crescita Therapeutics Inc. | -1.95 Million CAD | 689.417% |
| Knight Therapeutics Inc. | -2.89 Million CAD | 498.927% |
| MediPharm Labs Corp. | -18.25 Million CAD | 163.166% |
| OrganiGram Holdings Inc. | -242.73 Million CAD | 104.75% |
| Canopy Growth Corporation | -228.71 Million CAD | 105.041% |
| Willow Biosciences Inc. | -13.18 Million CAD | 187.46% |
| Auxly Cannabis Group Inc. | -19 Million CAD | 160.663% |